STOCK TITAN

RSU grant lifts Indivior (INDV) director holdings to 30,780 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Wheadon David E. reported acquisition or exercise transactions in this Form 4 filing.

Indivior Pharmaceuticals, Inc. director David E. Wheadon received a grant of 10,430 Restricted Stock Units (RSUs), each representing one share of common stock. The award is compensation rather than a cash purchase, at a stated price of $0.00 per share. Following this grant, his direct holdings total 30,780 shares. The RSUs vest the day before the next annual stockholders’ meeting after the grant date, if he continues serving the company until that vesting date.

Positive

  • None.

Negative

  • None.
Insider Wheadon David E.
Role null
Type Security Shares Price Value
Grant/Award Common Stock 10,430 $0.00 --
Holdings After Transaction: Common Stock — 30,780 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 10,430 shares Restricted Stock Units granted on 2026-05-13
Post-transaction holdings 30,780 shares Total common stock held directly after grant
Grant price $0.00 per share Stated price for RSU award
Restricted Stock Units (RSUs) financial
"Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock"
vest financial
"The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of the Issuer's stockholders financial
"on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wheadon David E.

(Last)(First)(Middle)
10710 MIDLOTHIAN TURNPIKE
SUITE 125

(Street)
NORTH CHESTERFIELD VIRGINIA 23235

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/13/2026A10,430(1)A$030,780D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.
Remarks:
/s/Alice Givens, Power of Attorney05/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Indivior (INDV) report for David E. Wheadon?

Indivior reported that director David E. Wheadon received a grant of 10,430 Restricted Stock Units. Each RSU represents a right to one share of common stock, increasing his equity-based compensation position with the company.

How many Indivior (INDV) shares does David E. Wheadon hold after this Form 4?

After the reported grant, David E. Wheadon holds 30,780 shares of Indivior common stock directly. This total includes the effect of the new 10,430-share RSU award disclosed in the Form 4 filing.

What are the terms of David E. Wheadon’s RSU grant at Indivior (INDV)?

The grant consists of 10,430 Restricted Stock Units, each equal to one share of Indivior common stock. The RSUs vest on the day immediately before the next annual stockholders’ meeting, contingent on his continued service to the company until that date.

Did David E. Wheadon buy or sell Indivior (INDV) shares in this Form 4?

He did not buy or sell shares on the market. Instead, he acquired 10,430 shares through a grant of Restricted Stock Units as compensation, reported with transaction code A for an award or other acquisition.

At what price were the Indivior (INDV) RSUs granted to David E. Wheadon?

The RSUs were granted at a stated price of $0.00 per share. This reflects that the award is equity compensation, providing shares at no cash cost to the director, subject to the vesting conditions described.